Latest Dana-Farber Cancer Institute Stories
Scientists at the Dana-Farber/Children's Hospital Cancer Center have developed an anti-cancer peptide that overcomes the stubborn resistance to chemotherapy and radiation often encountered in certain blood cancers when the disease recurs following initial treatment.
A hormone-depleting drug approved last year for the treatment of metastatic prostate cancer can help eliminate or nearly eliminate tumors in many patients with aggressive cancers that have yet to spread beyond the prostate.
Melanoma – the deadliest and most aggressive form of skin cancer – has long been linked to time spent in the sun.
A team of scientists, engineers and physicians from Brigham and Women's Hospital (BWH), Dana-Farber Cancer Institute (DFCI), Harvard Medical School (HMS), Massachusetts Institute of Technology (MIT), BIND Biosciences, Translational Genomics Research Institute (TGen), Wayne State University Karmanos Cancer Institute, and Weill Cornell Medical College have found promising effects of a first-in-class targeted cancer drug called BIND-014 in treating solid tumors.
- An armed gangster.